Legend Biotech Corporation Sponsored ADR $LEGN Stock: CenterBook Partners LP Decreases Position

CenterBook Partners LP cut its position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) by 23.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 344,879 shares of the company’s stock after selling 108,028 shares during the quarter. CenterBook Partners LP’s holdings in Legend Biotech were worth $6,860,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Assenagon Asset Management S.A. bought a new position in shares of Legend Biotech in the second quarter worth $55,307,000. Squarepoint Ops LLC grew its stake in shares of Legend Biotech by 60.4% during the second quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock valued at $22,216,000 after buying an additional 289,772 shares during the last quarter. Renaissance Technologies LLC increased its stake in Legend Biotech by 29.5% in the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock worth $9,439,000 after purchasing an additional 119,000 shares during the period. Candriam S.C.A. raised its holdings in Legend Biotech by 79.6% during the 1st quarter. Candriam S.C.A. now owns 470,292 shares of the company’s stock valued at $8,508,000 after buying an additional 208,477 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Legend Biotech by 343.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company’s stock valued at $7,361,000 after acquiring an additional 315,176 shares during the last quarter. Institutional investors own 70.89% of the company’s stock.

Legend Biotech Price Performance

Legend Biotech stock traded up $0.86 during midday trading on Friday, reaching $23.40. The company had a trading volume of 1,765,914 shares, compared to its average volume of 1,946,924. Legend Biotech Corporation Sponsored ADR has a 12-month low of $16.24 and a 12-month high of $37.50. The company has a market capitalization of $4.53 billion, a P/E ratio of -93.60 and a beta of 0.55. The firm’s fifty day simple moving average is $19.67 and its 200-day simple moving average is $22.10.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.07 by $0.02. Legend Biotech had a negative net margin of 7.21% and a negative return on equity of 8.71%. The firm had revenue of $387.50 million for the quarter, compared to analyst estimates of $355.96 million. During the same quarter in the previous year, the company earned $0.03 EPS. The business’s revenue for the quarter was up 51.9% compared to the same quarter last year. On average, analysts expect that Legend Biotech Corporation Sponsored ADR will post -0.08 EPS for the current fiscal year.

Insider Activity at Legend Biotech

In other Legend Biotech news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the company’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total value of $258,920.20. Following the completion of the transaction, the director owned 52,731 shares in the company, valued at $498,835.26. This represents a 34.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Carlos Santos sold 5,430 shares of the firm’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $9.14, for a total transaction of $49,630.20. Following the transaction, the chief financial officer directly owned 14,246 shares in the company, valued at $130,208.44. The trade was a 27.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.02% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. UBS Group reiterated a “buy” rating and set a $65.00 price target on shares of Legend Biotech in a research report on Monday, September 28th. Weiss Ratings lowered shares of Legend Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 19th. Barclays lowered their price objective on Legend Biotech from $74.00 to $68.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 13th. Royal Bank Of Canada cut their target price on shares of Legend Biotech from $58.00 to $56.00 and set an “outperform” rating for the company in a research note on Thursday, October 8th. Finally, JPMorgan Chase & Co. reduced their price objective on Legend Biotech from $35.00 to $33.00 and set a “neutral” rating on the stock in a research note on Friday, October 9th. Nine equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $54.69.

Get Our Latest Research Report on Legend Biotech

Legend Biotech Profile

(Free Report)

Legend Biotech Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. The company’s primary technology is chimeric antigen receptor T-cell (CAR-T) therapy, which genetically modifies a patient’s immune cells to recognize and attack cancer cells.

Legend Biotech’s leading product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma.

Featured Articles

Want to see what other hedge funds are holding LEGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report).

Institutional Ownership by Quarter for Legend Biotech (NASDAQ:LEGN)

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.